Connection

Jeffrey Jones to Rituximab

Back to Details
This is a "connection" page, showing publications Jeffrey Jones has written about Rituximab.
Jeffrey Jones
Connection Strength
0.144
Rituximab
  1. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 01; 180(2):259-266.
    View in: PubMed
    Score: 0.144
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.